Hansoh Pharma and Biotheus strengthen collaboration on EGFR/cMET Bispecific ADC development

CAR-T Digest - August 2020

15 Mar 2024: Hansoh Pharma and Biotheus strengthen collaboration on EGFR/cMET Bispecific ADC development

Biotheus and Hansoh Pharma expand strategic collaboration for antibody-drug conjugate (ADC) development
Hansoh Pharma gains exclusive worldwide rights to use Biotheus’ anti-EGFR/cMet bispecific antibody PM1080/HS-20117 for ADC product development
Biotheus stands to receive up to 5 billion RMB in upfront and milestone payments, plus royalties based on global net sales
PM1080/HS-20117, currently in phase I clinical trials, targets EGFR and cMet to inhibit tumor growth and survival
The collaboration aims to leverage Hansoh’s ADC expertise and Biotheus’ antibody capabilities to develop novel EGFR/cMet bispecific ADCs
Both companies express confidence in the potential clinical benefits and transformative treatment options for cancer patients globally